SEREarnings•globenewswire•
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Sentiment:Negative (30)
Summary
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire